Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.
April 11, 2019 at 12:00 PM EDT
MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc.(Nasdaq: CMTA) (“Clementia” or the “Corporation”) is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement under the Canada Business Corporations Act pursuant to which a wholly-owned subsidiary of Ipsen S.A. will acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share in cash upfront on completion of the transaction plus a deferred payment on the achievement of a future regulatory milestone in the form of a contingent value right of US$6.00 per share payable upon the U.S. Food and Drug Administration’s (FDA) acceptance of submission of a new drug application (NDA) filing for palovarotene for the treatment of multiple osteochondromas (MO) on or prior to December 31, 2024.
IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England...
IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023
Ipsen updates on QM-1114 regulatory process
IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.